^
    2d
    Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma. (PubMed, JCO Precis Oncol)
    Resistance to RET inhibitors can be acquired through RET copy-number gain and secondary mutations as well as NF1 loss-mediated MAPK pathway activation. This mechanism of resistance can be overcome with dual inhibition of RET and downstream RAS/MAPK signaling, demonstrating clinical potential in RET-mutant MTC.
    Journal
    |
    RET (Ret Proto-Oncogene) • NF1 (Neurofibromin 1)
    |
    RET mutation
    |
    Mekinist (trametinib) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
    5d
    Targeted therapy combined with local consolidative surgery for oligometastatic stage IVA lung adenocarcinoma with CCDC6-RET fusion: a case report. (PubMed, Front Oncol)
    This case demonstrates that for selected patients with advanced lung adenocarcinoma harboring a CCDC6-RET fusion and oligometastatic disease, initial systemic therapy with selpercatinib followed by local consolidative surgery is a feasible multimodal strategy. This is not a routine recommendation for stage IV lung cancer but requires individualized decision-making after multidisciplinary discussion in specific oligometastatic cases.
    Journal
    |
    RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • CCDC6-RET fusion
    |
    Retevmo (selpercatinib)
    6d
    RET Fusion-Positive Solid Tumor (PubMed, Gan To Kagaku Ryoho)
    Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene...In other solid tumors, positivity is less than 0.5%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET positive
    |
    Retevmo (selpercatinib)
    7d
    Durable response to selpercatinib in HOOK3-RET fusion positive, α-fetoprotein producing metastatic pancreatic ductal adenocarcinoma with intestinal-type differentiation. (PubMed, Oncol Lett)
    The patient did not respond to gemcitabine and cisplatin-based systemic chemotherapy. Selpercatinib, a selective inhibitor of receptor tyrosine kinase RET, blocks RET kinase activity by binding to its adenosine triphosphate-binding site, thus preventing the kinase from phosphorylating substrates and halting oncogenic signaling. The patient was treated with selpercatinib, which produced a durable response lasting over 15 months in this chemotherapy-refractory patient, highlighting the efficacy of selpercatinib in HOOK3-RET fusion-positive pancreatic cancer.
    Journal
    |
    RET (Ret Proto-Oncogene) • AFP (Alpha-fetoprotein)
    |
    RET fusion • RET positive
    |
    cisplatin • gemcitabine • Retevmo (selpercatinib)
    8d
    Selpercatinib Improves EFS in RET Fusion-Positive NSCLC. (PubMed, Cancer Discov)
    Results from LIBRETTO-432 demonstrate that adjuvant selpercatinib yields a substantial improvement in event-free survival for patients with early-stage RET fusion-positive non-small cell lung cancer. Experts say the findings establish selpercatinib as a new standard of care for this rare disease, although questions remain over identifying patients and access to screening.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET positive
    |
    Retevmo (selpercatinib)
    9d
    Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. (PubMed, N Engl J Med)
    Among patients with stage II or IIIA RET fusion-positive NSCLC, event-free survival was significantly longer with adjuvant selpercatinib than with placebo. (Funded by Lilly; LIBRETTO-432 ClinicalTrials.gov number, NCT04819100.).
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET positive
    |
    Retevmo (selpercatinib)
    9d
    RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases. (PubMed, Cell Death Dis)
    Using two mouse studies modeling multi-organ metastases and breast tumor formation in the brain, we observed that RET inhibition significantly prevented the circulating tumor cells from forming brain metastases and suppressed the growth of intracranially implanted tumor cells. Together, our findings demonstrated that RET functions as a novel mediator of BCBM and that RET inhibitors showed promising efficacy for BCBM.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • RET (Ret Proto-Oncogene)
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib)
    10d
    Successful selpercatinib treatment of metastatic medullary thyroid cancer carrying rare RET variant (PubMed, Magy Onkol)
    This case underscores the value of liquid biopsy detected mutations in guiding targeted therapy. Clinical, biochemical, and radiological findings support the potential use of selective RET tyrosine kinase inhibitors for this rare mutation. Serum calcitonin serves as a reliable quantitative biomarker of therapeutic efficacy.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    Retevmo (selpercatinib) • Prolia (denosumab)
    12d
    Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib. (PubMed, Front Oncol)
    Demonstrated analytical and clinical performance of F1CDx led to the pan-tumor approvals from the U.S. Food and Drug Administration (FDA) in 2023 and the Japan Ministry of Health, Labour and Welfare (MHLW) in 2024 of F1CDx to identify RET fusions in solid tumor patients for treatment with selpercatinib. F1CDx is an accurate, reliable, FDA- and MHLW-approved method for the pan-tumor identification of RET fusions for treatment with selpercatinib.
    Journal • Companion diagnostic • Pan tumor
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    FoundationOne® CDx
    |
    Retevmo (selpercatinib)
    14d
    Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report. (PubMed, Lung Cancer (Auckl))
    The observation is hypothesis-generating rather than proof of sensitivity. This case provides a reference for precision treatment strategies after resistance to RET inhibitors.
    Journal
    |
    RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • RET mutation • CCDC6-RET fusion
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib)
    14d
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • dexamethasone • Erivedge (vismodegib) • melphalan • dactinomycin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • hydroxyurea